Background: There is controversy over "labelling" people with prediabetes. Using serial crossexamined prevalence of cardio-renal burdens in U.S. adults with prediabetes over time and compared patterns with other glycemic groups.
INTRODUCTION
There are concerns that current diagnostic thresholds for prediabetes are too low and that labeling people as having prediabetes leads to "medicalization" of the condition.(1) Critics argue that prediabetes is a creation of the pharmaceutical industry and that a substantial portion of people with prediabetes never progress to diabetes. Proponents of the prediabetes "diagnosis" argue that several longitudinal studies, meta-analyses, (2, 3) and rates of high progression noted in the control groups of intervention trials (4, 5) provide adequate evidence that people with prediabetes have three-to eleven times higher annual diabetes incidence than the general population and that the benefits and opportunity to intervene with lifestyle modification (LSM) outweighs the potential negative externalities. Furthermore, while prediabetes is associated with excess future risk of cardiovascular disease, (6) little is known about the prevalence of cardio-renal risk factors and disease in prediabetes. Also, it remains unknown whether identification of these individuals provides an opportunity to assert particular attention to management of these risk factors.
To further inform this debate, we used nationally-representative data from 1988 to 2014 to examine trends in prevalence, treatment, and control of hypertension, dyslipidemia, and smoking; average 10-year cardiovascular disease (CVD) event risk; and presence of cardiorenal co-morbidities in the US adult population by glycemic status (i.e. those with prediabetes, diagnosed diabetes, undiagnosed diabetes, and normal glycemia). Greater emphasis on identification, large randomized trials of diabetes management, (7) (8) (9) along with a movement focused on quality benchmarking against guideline-recommended care goals have led to successive improvements in cardio-renal risk factor profiles of persons with diagnosed diabetes nationally. (10, 11) To date, however, it is unclear whether people with prediabetes also experienced similar improvements. These findings not only contribute nationally representative data to controversies regarding prediabetes, but also help identify gaps in care for specific groups that can be addressed to optimize population cardiovascular health in the U.S.
METHODS

Study design and participants
We analyzed data from successive National Health and Nutrition Examination Surveys (NHANES) over 25 years (1988-1994, 1999-2004, 2005-2010, and 2011-2014) . The National Center for Health Statistics (NCHS) employs a complex multi-stage sampling approach to recruit sample populations such that each two-year NHANES cycle is representative of the nation's non-institutionalized civilians. The NCHS Research Ethics Review Board approved NHANES. All participants provided informed consent prior to participation.
Details regarding sampling methods, survey instruments, and data collection have been described elsewhere. (12, 13) Briefly, social and demographic characteristics were obtained via interviewer-administered questionnaires. Data regarding anthropometrics, blood pressure (BP, mmHg), and blood and urine specimens were collected in mobile examination centers. From these, fasting plasma glucose (FPG, mg/dl), glycated hemoglobin (HbA1c, %), non-HDL cholesterol (mg/dl), and urinary creatinine and albumin were estimated using standardized laboratory techniques (Appendix A).
Response rates for 1988-2014 NHANES ranged from 75-80%. Our analyses included all non-pregnant participants aged 20 years and older with no self-reported diabetes that fasted for a minimum of eight hours and all participants with self-reported diabetes regardless of fasting status. In total, our analysis included 7916 (1988) (1989) (1990) (1991) (1992) (1993) (1994) , 6684 (1999-2004) , 5750 (2005) (2006) (2007) (2008) (2009) (2010) , and 5463 participants (2011-2014).
Variable Definitions
Diagnosed diabetes was defined by participants' positive response to the question, "Other than during pregnancy, have you ever been told by a doctor or health professional that you have diabetes or sugar diabetes?" For those reporting no diabetes diagnosis, we classified undiagnosed diabetes as FPG ≥126mg/dl (7.0mmol/L) or HbA1c ≥6.5% (48mmol/mol), prediabetes as FPG 100-125mg/dl (5.6-6.9mmol/L) or HbA1c 5.7-6.4% (39-47mmol/mol), and normal glycemic status as FPG <100mg/dl (5.6 mmol/L) and HbA1c <5.7% (39mmol/ mol). In sensitivity analyses, we defined prediabetes with higher FPG (110-125mg/dl [6.1-6.9mmol/L]) and/or higher HbA1c (≥6.0% [42mmol/mol]) thresholds to examine if and how prevalence of prediabetes and cardio-renal co-morbidities varied.
Participant Characteristics
We reported mean age, sex, race/ethnicity (non-Hispanic white vs. others), insurance status (any vs. none), and education (< high-school vs. at least high-school education) at time of survey. We used poverty-income ratio, an indicator of income relative to inflation-adjusted family need to categorize income (above vs. at or below poverty level).(14) We used measured height, weight, and waist circumference to calculate body mass index (BMI; weight divided by height squared [kg/m 2 ]) and waist-to-height ratio (waist divided by height).
Cardiovascular Risk Factors
We defined hypertension as self-reported anti-hypertensive drug use and/or measured BP≥140/90mmHg. We defined dyslipidemia as self-reported lipid-lowering drug use and/or non-HDL cholesterol≥160mg/dl. To estimate smoking prevalence, we used self-reports of ever smoking (reporting ≥100 cigarettes smoked in their lifetime) and classified smoking status as "current" (positive response when asked about smoking at the time of survey), "former" (positive response to ever smoking, but negative to current); or "never" (negative response to ever smoking).
Care Goal Achievement
The BP goal (<140/90mmHg) was based on the Seventh Joint National Committee. (15) For lipid control, we used non-HDL cholesterol<130mg/dl (2.6mmol/L) which corresponds with the LDL cholesterol<100mg/dl (2.2mmol/L) goal articulated in the American Diabetes Association guidelines. (16) We used not currently smoking as the tobacco control goal.
Cardio-renal complications of Diabetes
We calculated average 10-year CVD event risk using three risk scores: the modified Framingham score, (17) the United Kingdom Prospective Diabetes Study (UKPDS) diabetesspecific tool, (18) and the more contemporary atherosclerotic cardiovascular disease (ASCVD) risk calculator. (19) We described previous myocardial infarction and stroke based on participant self-report.
We examined different markers of chronic kidney disease (CKD): median urinary albumin:creatinine ratio (ACR) and ACR≥30 mg/g (signifying moderate-to-severe albuminuria), as well as mean estimated glomerular filtration rate (eGFR) and eGFR<60ml/min/1.73m 2 (stages III-V) using the CKD-EPI equation. (20) We also estimated prevalence of hyperfiltration (eGFR>135ml/min/1.73m 2 ), an early indicator of hyperglycemia-related renal damage.(21)
Statistical analysis
We used SAS version 9.3 (SAS Institute Inc., Cary, NC) and SUDAAN version 11.0 (Research Triangle Institute, Research Triangle Park, NC) to adjust for complex survey designs. To account for differential probabilities of selection and non-response, we used interview weights from individuals with diagnosed diabetes and fasting weights for individuals without diagnosed diabetes so that the sum of the sampling weights added to the total US population. Missing data ranged from 1% (smoking status) to 3.5% (CKD), and sample sizes were reduced for each specific analysis where data for the dependent variable were missing.
For each glycemic group (diagnosed diabetes, undiagnosed diabetes, prediabetes, normal glycemia) in each period, we described socio-demographic and clinical characteristics, and, using multiple logistic regression, we calculated prevalence of hypertension and dyslipidemia adjusted for age, sex, and race/ethnicity. We tested for trends in distributional differences in these characteristics and CVD risk factors in successive periods using adjusted Wald F tests.
Among those with hypertension, we estimated the proportion treated based on self-report. Then, for those treated, we assessed proportions of adults that achieved BP <140/90mmHg (i.e. "controlled") and those who did not ("uncontrolled"). This same approach was repeated for dyslipidemia.
For tobacco use, we reported proportions of never, former, and current smokers for each glycemic group for each survey period.
For each group in each time period, we also reported average 10-year CVD event risk and estimated prevalence of myocardial infarction and stroke. In sensitivity analyses, we estimated CVD event risk after excluding people with a history of myocardial infarctions, strokes, and congestive heart failure.
For CKD, we reported mean albuminuria and eGFR, prevalence of proteinuria and reduced eGFR separately and together, and prevalence of hyperfiltration to explore whether patterns of renal disease varied by classification method.
For all estimates of prevalence, care goal achievement, and mean levels, we calculated the predicted changes between 1988-94 and 2011-14 using an interaction term of glycemic status by survey period in logistic regression models adjusted for age, sex, and race/ ethnicity.
We reported 95% confidence intervals (95%CI) for all data and used p<0.05 as an indicator of statistical significance.
Role of the Funding Source
The NCHS funds NHANES surveys, but did not play any role in the design, conduct, and reporting of these analyses.
RESULTS
Over successive survey periods between 1988-1994 and 2011-2014 ( Table 1) , prevalence of prediabetes and diagnosed diabetes increased while undiagnosed diabetes and normal glycemia decreased. Throughout the period, prevalence (and absolute numbers) of each prediabetes subgroup increased over time, though there was wide variation in absolute numbers with prediabetes by different definition permutations. In 2011-2014 surveys, using the most specific (FPG 100-125mg and A1c 5.7-6.4%) and sensitive definitions (FPG 100-125mg or A1c 5.76.4%), prediabetes prevalence varied from 11.0% (19.5 million adults) to 34.7% (78.5 million), respectively. Across all glycemic groups, over the period from 1988-1994 to 2011-2014 surveys, mean age of US adults remained stable; sex distributions stayed largely the same except for women accounting for larger proportions of those with prediabetes; and higher proportions over time self-identified as minority race/ethnicities and reported completing high school education. Mean BMI and WHtR increased substantially in every group. Over time, larger proportions of people with undiagnosed diabetes, prediabetes, and normoglycemia were living in poverty. Of note, for people with diagnosed diabetes, the average number of years since diagnosis increased from 9.5 to 11.6 years between 1988-1994 and 2011-2014 surveys.
Prevalence of hypertension and dyslipidemia
Across survey periods ( , remained relatively stable in those with undiagnosed diabetes and prediabetes, and decreased in normoglycemic individuals (−6.0 ppt [−9.9, −2.1]). Hypertension and dyslipidemia prevalence estimates were similar or slightly higher for prediabetes subgroups defined using more specific thresholds (Appendix B), and patterns of prevalence changes over time (9-10 ppt increases in hypertension and no change in dyslipidemia) were similar.
Treatment and control among those with hypertension or dyslipidemia
In successive periods from 1988-1994 to 2011-2014, among those with hypertension ( Figure 1 : A), proportions of adults with prediabetes using BP-lowering medications increased from 53.9% to 81.4% (p<0.001). Similar increases in anti-hypertensive treatment were also evident in other groups. Achievement of BP treatment targets increased in every group over time, except for those with undiagnosed diabetes; by 2011-2014, adults with undiagnosed diabetes were 20-30 ppt less likely to meet BP goals compared to all other groups (36.6% vs. 55-65%, p-values<0.001). Mean systolic and diastolic BP levels over time corroborate these findings (Table 3) , and this pattern was especially evident among those with diagnosed hypertension.
From 1988-1994 to 2011-2014, among those with dyslipidemia ( Figure 1 : B), use of lipidlowering treatments increased in all groups: similarly among adults with prediabetes (6.6% to 40.2%, p<0.001), undiagnosed diabetes (7.7% to 35.8%, p<0.001), and normoglycemia (7.7% to 34.5%, p<0.001), but much more markedly in people with diagnosed diabetes (from 11.0% to 72.0%, p<0.001). By 2011-2014, there was a marked difference in achievement of guideline-recommended lipid levels between those with diagnosed diabetes (57%) versus all other glycemic groups (~29-33%, p-values<0.001). Mean non-HDL cholesterol levels over time declined significantly in every glycemic group (Table 3) ; the magnitude of reductions were largest in adults with diagnosed diabetes.
(ranging from −3.2 [ASCVD] to −6.7 [UKPDS] ppt]) compared to undiagnosed (ranging from −1.4 [ASCVD] to −4.4 [UKPDS] ppt), prediabetes (ranging from −1.9 [ASCVD] to −2.7 [UKPDS] ppt), and normoglycemic adults (approximately 1.0 ppt). History of previous myocardial infarction and previous stroke have largely remained stable for every group over time. Excluding adults with CVD history, CVD event risk estimates and declines were no different over time (Appendix C). Estimates and trends were consistent across all definitions of prediabetes (Appendix D).
Overall, there was no change in prevalence of any CKD for those with diagnosed or undiagnosed diabetes or prediabetes; only adults with normal glycemia experienced a 3.4ppt increase over time ( Table 5 ). Patterns by specific CKD markers varied by group over time: for example, median ACR increased in every group except in those with diagnosed diabetes, where a statistically significant reduction was seen. Glomerular filtration declined in all groups, and significantly among those with diagnosed diabetes and normal glycemia. Across all definitions of prediabetes, prevalence estimates and trends were consistent (Appendix E).
DISCUSSION
Using sensitive and specific definitions, in the 2011-2014 period, over one third of US adults with impaired fasting glucose or elevated A1c levels had hypertension, over half had dyslipidemia, and over a quarter smoked. Approximately 12% had some form of CKD, 6% reported a previous myocardial infarction or stroke, and average 10-year CVD event risk was approximately 6%. The absolute number of people with prediabetes in the US varied widely based on the definition used. However, even with the most sensitive definitions, the prevalence of cardio-renal risks and co-morbidities remained the same; this implies that the absolute volume of people affected by these co-morbidities outnumbered those with diabetes and similar risks or co-morbidities. Our data also show much room for improvement among people with prediabetes, especially for lipid-lowering where only about 40% of those with dyslipidemia were receiving treatment.
Adjusted for age, sex, and race/ethnicity differences over time and compared to other glycemic groups, adults with diagnosed diabetes have benefited from more BP-and lipidlowering treatment; exhibited greater BP and lipid control in every survey period since 1988-1994; and experienced impressive declines in ten-year probability of having a CVD event. Over the years, despite an increase in the average duration of diabetes -a major risk factor for diabetes complications, itself-there have been no changes in prevalence of myocardial infarction, stroke, or renal impairment. Longer diabetes duration with similar mean age and prevalence of complications may imply that diabetes is being diagnosed earlier in the disease process or care received by diagnosed diabetic adults may be counteracting the influence of longer diabetes duration, or both.
In the context of ongoing debates about "medicalizing" prediabetes, these data contribute some thought-provoking considerations. First, even if one contends that rates of progression from prediabetes to diabetes are not especially high, our data show that the proportions and absolute numbers of people affected by risk factors and cardio-renal co-morbidities are concerning. Other data corroborate associations between prediabetes and cardio-renal complications. (22, 23) Furthermore, per capita health expenditures for adults with prediabetes are higher than expenditures in the general public and grow when people progress to diabetes. (24) Given that there were also contentions regarding lower (e.g., FPG≥100mg/dl [5.6mmol/L]) versus higher diagnostic thresholds (FPG≥110mg/dl [6.0mmol/L]), we examined a range of cutpoints and noted similar findings, albeit the absolute numbers with prediabetes were smaller and the proportions affected by cardio-renal risks and co-morbidities were higher when we used more specific definitions. With regard to medicalization leading to treatment, gaps in use of lipid-lowering medications in people with prediabetes were large. These may reflect physician apprehension given the added risk of diabetes with statin use;(25) the CVD risk reduction benefits -especially for primary prevention-versus the increased risk of diabetes of statins -especially among people with prediabetes-remains a contentious issue. (26) Second, in the case of diabetes, our data suggest that diagnosed diabetes status was associated with significantly greater treatment and achievement of BP and cholesterol care goals. Previous studies have also shown improvements in achievement of diabetes care goals (27) and, in parallel, more impressive declines in macrovascular disease -especially myocardial infarction and stroke-in people with diabetes than no diabetes between 1990 and 2010.(28) Persons with diagnosed diabetes may have received more attentive care, treatments, and focus on achieving care goals. Another consideration to contextualize our findings is that diagnosis may be occurring earlier over time. There may be lessons here for cases of undiagnosed diabetes and prediabetes. Only one in ten people with prediabetes is aware of his/her elevated glucose, (29) and, as was the case for diagnosed diabetes, identification might prompt earlier treatments for their co-morbidities to lower cardio-renal risk.
Third, and foremost, earlier intervention is beneficial. Robust randomized controlled trials in multiple countries have shown that intensive LSM (eating fiber rich foods, being physically active, and managing weight) for people with impaired glucose tolerance can slow progression to diabetes, (30, 31) and are associated with numerous other benefits (regression to normoglycemia in a third of cases;(32) lower need for BP-and lipid-lowering medications;(33) lower disability; less obstructive sleep apneas; less retinopathy; and less urinary incontinence (34) ). In the Diabetes Prevention Program study, intensive LSM was provided to placebo and metformin study groups upon discontinuation of the randomized trial at 2.8years, and still, cumulative diabetes incidence in the original LSM group remained 34% and 27% lower even 10 and 15years after randomization, respectively. (30) In addition, long-term reductions in all afore-mentioned conditions, albeit small due to both arms being exposed to the intervention, remained greater in the intervention arm. This is strong proof that the earlier the intervention is started, the higher the likelihood of delaying progression and associated costs.
It is important to clarify that we are not endorsing earlier initiation of glucose-lowering medications to "prevent" diabetes -recent aggregated data showed that these have no impact on the pathophysiology of diabetes and only serve to suppress glucose for the period they are taken. (35) Earlier intervention with LSM, on the other hand, has enduring benefits and are associated with collateral benefits such as reductions in BP and cholesterol,(36) less need for medications, (37) and possibly less CKD. (38) LSM interventions might also offer a promising opportunity to preserve quality of life for longer as declines in excess diabetesrelated mortality has led to an expansion in the number of years that people with diabetes live with disabilities;(39) earlier intervention might help shift the distribution of disease and disability later, which may also lower long-term costs.
Efforts to identify diabetes earlier may be buoyed by recent modifications to the US Preventive Services Task Force diabetes screening guideline, which recommends screening all adults aged 40-70 years who are overweight or obese. (40) The new standards may be more sensitive than previous recommendations as they include the added value of identifying prediabetes earlier as an opportunity to modify disease trajectory.
This study has some limitations. We used successive surveys which offer important snapshots, but only reflect the risk profile of the population at the time of survey. The crosssectional design is limited in terms of our ability to truly evaluate longitudinal associations between prediabetes and excess risk of cardiovascular and renal diseases over time; this is the purview of prospective cohort studies. That said, our study provides valuable information on prevalence of cardio-renal risks and calculated levels of early organ damage for US adults for each glycemic group. Definitions of glycemic groups may not meet more strict clinical criteria of separate, repeated measures to classify glycemic status. This may have resulted in overestimates of diabetes and prediabetes; still, single measure definitions are commonly used in epidemiologic studies and were consistently applied across surveys making our findings regarding trends internally valid. We defined prediabetes using FPG and HbA1c, but not 2-hour postprandial glucose as it is logistically challenging to collect these samples in large epidemiological studies. As such, our estimates of prediabetes are lower than if impaired glucose tolerance (IGT) were included, and indeed, there is evidence that IGT is more strongly related to cardio-renal risks and disease; as such, our estimates are likely conservative. For BP and lipid control, denominators (those with hypertension or dyslipidemia) may be subject to ascertainment bias; to provide a more comprehensive interpretation of this, we examined mean BP and lipid levels for all glycemic groups irrespective of diagnostic status and also among those with hypertension and dyslipidemia separately. Medications to lower BP are used for non-hypertension reasons such as migraine headache prophylaxis and this may have affected our estimates of hypertension prevalence and control, albeit by a small amount. Self-reported data may be subject to recall and social desirability biases.
In terms of strengths, our analyses included US adults across the spectrum of glycemia and offers perspectives from successive nationally representative surveys on risk factors, treatment, adherence, and complications profiles. We adjusted all estimates to remove the influence of differences and changes in age, sex, and race/ethnicity across glycemic groups over time. We used non-HDL cholesterol levels instead of total or LDL-cholesterol fractions so that there was no exclusion of non-fasted individuals and non-HDL cholesterol is also gaining recognition in clinical practice. Also, we used categorical (e.g., treated vs. not), continuous (e.g., mean BP), and global (e.g., older and contemporary CVD risk estimators) performance indicators to provide a comprehensive picture of trends over time.
The absolute number of adults with prediabetesis large, no matter which definitions are used. More importantly, substantial portions of these adults have co-morbid cardio-renal risk factors and disease. These data call for a less diabetes-centric view of prediabetes and instead conceptualize detection as an opportunity for early intervention; i.e. identifying and addressing prediabetes and related cardio-renal risk factors and co-morbidities is an investment in broader population cardio-metabolic health.
RESEARCH IN CONTEXT
Evidence before this study
Despite meta-analyses and randomized clinical trials showing that people with prediabetes have 5-10 times faster progression to diabetes than the general public, critics argue that not all individuals with prediabetes develop diabetes and that labeling them unnecessarily medicalizes these people.
Added value of this study
To our knowledge, this is the first study to examine the overall cardio-metabolic profiles of adults with prediabetes. Using data from successive nationally-representative crosssectional U.S. surveys from the early 1990's, our study shows growth in cardiac and renal risk factors and diseases in people with prediabetes, some improvements in treatment of blood pressure and cholesterol, and reductions in smoking. Our study is also the first to compare these trends over time with those seen in people with diagnosed and undiagnosed diabetes, and those without any glucose regulation abnormalities.
Implications of all the available evidence
Prediabetes is exceedingly common and approximately half of these people have comorbidities like hypertension, dyslipidemia, or both, leading to excess cardiovascular and renal disease risk. These findings did not change with different definitions of prediabetes. Furthermore, compared to people with prediabetes, undiagnosed diabetes, or no glycemic abnormalities, people with diagnosed diabetes have enjoyed a much higher likelihood of receiving blood pressure-and cholesterol-lowering treatments and declining incidence of macrovascular complications over time. Given the vast numbers of people with prediabetes, even if identification of glucose abnormalities resulted in marginally greater engagement in healthy behaviors and treatment of co-morbidities like blood pressure, cholesterol, and smoking cessation, it is likely that population cardio-metabolic and renal health would improve. Ali Undiagnosed diabetes was defined as no self-reported diabetes diagnosis and FPG ≥126mg/dl (7.0mmol/L) or HbAlc ≥6.5% (48mmol/mol).
Characteristics of prediabetes population was for the group defined as no-self reported diabetes and FPG 100125mg/dl (5.6-6.9mmol/L) or HbA1c 5.7-6.4% (39-47mmol/mol).
Normal glycemic status was defined by no reported diabetes diagnosis and FPG <100mg/dl (5.6 mmol/L) and HbA1c <5.7% (39mmol/mol). † Population size was estimated for the civilian, non-institutionalized US adult population aged 20 years and older using Current Population Survey population totals and the proportion in each glycemic group.
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